CSIMarket
 


Ionis Pharmaceuticals Inc  (IONS)
Other Ticker:  
 

Ionis Pharmaceuticals Inc's Total Debt to Equity

IONS's quarterly Total Debt to Equity and Total Debt, Equity growth


Despite a net increase in borrowings by 15.46%, Ionis Pharmaceuticals Inc managed to enhance Total Debt to Equity in the forth quarter 2023 to 1.68, surpassing the average for Ionis Pharmaceuticals Inc's Total Debt to Equity.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 24 other companies have achieved lower Total Debt to Equity than Ionis Pharmaceuticals Inc in the IV Quarter 2023. While Total Debt to Equity total ranking has improved so far in the forth quarter 2023 to 817, from total ranking in the third quarter 2023 at 2452 .

Explain Debt to Equity Ratio?
What is the structure of IONS´s Total Debt?
How valuable is the IONS´s Equity?


IONS Total Debt to Equity (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Equity Change -38.1 % -55.54 % -36.95 % 7.98 % 7.22 %
Y / Y Total Debt Change -4.63 % -17.33 % -6.92 % -14.74 % -8.03 %
Total Debt to Equity MRQ 1.68 1.78 1.3 1.1 1.09
IONS's Total Ranking # 817 # 2452 # 2384 # 938 #
Seq. Equity Change 22.58 % -35.17 % -15.07 % -8.3 % -11.96 %
Seq. Total Debt Change 15.46 % -11.11 % 0.12 % -7.18 % 0.08 %



Total Debt to Equity forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 25
Healthcare Sector # 77
Overall Market # 817


Total Debt to Equity Statistics
High Average Low
5.03 1.18 0.29
(Dec 31 2016)   (Dec 31 2019)




Financial Statements
Ionis Pharmaceuticals Inc's Equity $ 387 Millions Visit IONS's Balance sheet
Ionis Pharmaceuticals Inc's Total Debt $ 648 Millions Visit IONS's Balance sheet
Source of IONS's Sales Visit IONS's Sales by Geography


Cumulative Ionis Pharmaceuticals Inc's Total Debt to Equity

IONS's Total Debt to Equity for the trailling 12 Months

IONS Total Debt to Equity

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Equity TTM Growth -38.1 % -55.54 % -36.95 % 7.98 % 7.22 %
Y / Y Total Debt TTM Growth -4.63 % -17.33 % -6.92 % -14.74 % -8.03 %
Total Debt to Equity TTM 1.4 1.25 1.1 1 1.05
Total Ranking TTM # 98 # 1562 # 132 # 171 #
Seq. Equity TTM Growth 22.58 % -35.17 % -15.07 % -8.3 % -11.96 %
Seq. Total Debt TTM Growth 15.46 % -11.11 % 0.12 % -7.18 % 0.08 %


On the trailing twelve months basis Due to the net new borrowings of 15.46% during the trailing twelve months finishing in the IV Quarter 2023, cumulativeTotal Debt to Equity improved to 1.4, above the Ionis Pharmaceuticals Inc's average Total Debt to Equity.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 11, during the past 12 months, other companies have achieved lower Total Debt to Equity than Ionis Pharmaceuticals Inc. While Total Debt to Equity total ranking has improved so far to 98, from total ranking in previous 12 month period at 1562.

Explain Debt to Equity Ratio?
What is the structure of IONS´s Total Debt?
How valuable is the IONS´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 12
Healthcare Sector # 24
Within the Market # 98


trailing twelve months Total Debt to Equity Statistics
High Average Low
2.31 0.6 0
(Sep 30 2017)   (Jun 30 2017)




Companies with similar Total Debt to Equity in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Total Debt to EquityDec 31 2023 MRQ Total DebtDec 31 2023 MRQ Equity
Nascent Biotech Inc  4.12 $ 0.125  Millions$ 0.030  Millions
Collegium Pharmaceutical Inc   3.41 $ 667.171  Millions$ 195.431  Millions
Eterna Therapeutics Inc   3.03 $ 6.773  Millions$ 2.233  Millions
Milestone Pharmaceuticals inc   2.97 $ 49.772  Millions$ 16.771  Millions
Teva Pharmaceutical Industries Limited  2.44 $ 19,833.000  Millions$ 8,126.000  Millions
Amicus Therapeutics inc   2.42 $ 387.858  Millions$ 160.174  Millions
Eli Lilly And Company  2.32 $ 25,225.300  Millions$ 10,863.700  Millions
Arcutis Biotherapeutics Inc   2.28 $ 201.799  Millions$ 88.667  Millions
Blueprint Medicines Corporation  2.13 $ 278.011  Millions$ 130.609  Millions
Travere Therapeutics Inc   1.88 $ 377.263  Millions$ 200.810  Millions
Phibro Animal Health Corporation  1.75 $ 474.898  Millions$ 270.803  Millions
Ionis Pharmaceuticals Inc  1.68 $ 648.453  Millions$ 386.686  Millions
Eyenovia inc   1.59 $ 14.287  Millions$ 8.999  Millions
Jazz Pharmaceuticals Plc  1.53 $ 5,712.942  Millions$ 3,736.997  Millions
G1 Therapeutics Inc   1.46 $ 51.557  Millions$ 35.386  Millions
Xoma Corporation  1.40 $ 124.061  Millions$ 88.721  Millions
Alimera Sciences Inc   1.40 $ 64.489  Millions$ 46.170  Millions
Biovie Inc   1.36 $ 10.195  Millions$ 7.491  Millions
Catalent Inc   1.36 $ 5,005.000  Millions$ 3,687.000  Millions
Bristol myers Squibb Company  1.35 $ 39,772.000  Millions$ 29,485.000  Millions
Emergent Biosolutions Inc   1.32 $ 860.200  Millions$ 649.300  Millions
Zoetis Inc   1.32 $ 6,567.000  Millions$ 4,991.000  Millions
Soligenix inc   1.29 $ 3.261  Millions$ 2.522  Millions
Summit Therapeutics Inc   1.29 $ 100.000  Millions$ 77.692  Millions
Clene Inc   1.23 $ 16.521  Millions$ 13.390  Millions
Lexicon Pharmaceuticals Inc   1.07 $ 99.508  Millions$ 93.110  Millions
Merck and Co Inc   0.93 $ 35,055.000  Millions$ 37,635.000  Millions
Elanco Animal Health Inc  0.93 $ 5,774.000  Millions$ 6,223.000  Millions
Viatris Inc   0.89 $ 18,131.500  Millions$ 20,467.400  Millions
Perrigo Company Plc  0.85 $ 4,073.400  Millions$ 4,767.900  Millions

Date modified: 2024-02-22T10:01:01+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com